Overview

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Status:
Completed
Trial end date:
2016-05-11
Target enrollment:
0
Participant gender:
All
Summary
This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734). The primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo by showing a reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions from Week 12 to Week 24 in patients with relapsing multiple sclerosis (RMS).
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Celgene
Treatments:
Ozanimod
Criteria
Inclusion Criteria:

- Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria

- Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at Baseline

Exclusion Criteria:

- Secondary or primary progressive multiple sclerosis